Sign in Subscribe
Cancer research

COVID-19 Vaccines Show Promise in Prolonging Cancer Patients' Lives

Strategic Insights

— 2 min read

Researchers from the University of Florida and the University of Texas MD Anderson Cancer Center have found that COVID-19 mRNA vaccines can activate a powerful immune response that boosts the effectiveness of immunotherapy in cancer patients. Studies have shown that patients who received the vaccine within 100 days of starting immunotherapy were more than twice as likely to be alive after three years compared to those who didn't receive the vaccine.

The study, published in Nature, involved a retrospective analysis of over 1,000 patients who had received immunotherapy and the COVID-19 vaccine. The results showed that the vaccinated group had a 3-year overall survival rate of 55.7%, compared to 30.8% in the unvaccinated group. This translates to a 49% reduction in cancer-associated mortality risk.

The researchers attribute the vaccine's effectiveness to its ability to "wake up" the immune system and trigger a surge of type-I interferons. This, in turn, activates the body's innate immune system, priming T-cells to recognize and attack tumor-associated antigens.

The study's lead author, Elias Sayour, said, "If these results are confirmed in a randomised phase III trial, we believe it could revolutionise the field and help patients across the globe access a widely available low-cost alternative."

Key Takeaways:

  • COVID-19 mRNA vaccines can activate a powerful immune response that boosts the effectiveness of immunotherapy in cancer patients.
  • Patients who received the vaccine within 100 days of starting immunotherapy were more than twice as likely to be alive after three years compared to those who didn't receive the vaccine.
  • The vaccinated group had a 3-year overall survival rate of 55.7%, compared to 30.8% in the unvaccinated group, resulting in a 49% reduction in cancer-associated mortality risk.
  • The vaccine's effectiveness is attributed to its ability to "wake up" the immune system and trigger a surge of type-I interferons.
  • The study's results have implications for widening access to lifesaving cancer treatments, particularly for patients in low-income countries.
  • Researchers are planning to test COVID-19 mRNA vaccines alongside immune checkpoint inhibitor treatment in a nationwide randomised clinical trial in lung cancer patients.

Statistics:

  • 1,000+ patients were involved in the retrospective analysis.
  • 55.7% of patients in the vaccinated group survived after three years, compared to 30.8% in the unvaccinated group.
  • The vaccine reduced cancer-associated mortality risk by 49%.
  • 49% is the approximate reduction in cancer-associated mortality risk.

Sources:

  • [1] Gavi, the Vaccine Alliance. (2025, October 31). COVID-19 vaccines could prolong the life of cancer patients by activating a powerful immune response that boosts the effectiveness of immunotherapy.
  • [2] Nature. (2025). Retrospective analysis of pandemic cancer survival with animal studies of the mechanism of action.
  • [3] The Conversation. (2025). Op-ed: "COVID-19 mRNA vaccines act like an alarm, triggering the body's immune system to recognize and kill tumor cells and overcome the cancer's ability to turn off immune cells."
  • [4] VaccinesWork. (2025). Interview with Dr. Elias Sayour.

Read more